Summary：GeneDx Holdings Corp. Investors Can Take Action Against Securities Fraud Allegations NowLOS ANGELES,

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

GeneDx Holdings Corp. Investors Can Take Action Against Securities Fraud Allegations Now

LOS ANGELES, June 15, 2026 - The Schall Law Firm, a renowned national shareholder rights litigation firm, is alerting investors to a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for alleged violations of federal securities laws, specifically §§10(b) and 20(a) of the Securities Exchange Act of 1934.

The lawsuit stems from allegations that GeneDx made materially false and misleading statements regarding its business operations and financial condition, potentially deceiving investors and causing them significant financial losses. Investors who purchased GeneDx securities between February 10, 2023, and May 1, 2024, are encouraged to participate in the class action lawsuit.

Key developments in the case include the revelation of previously undisclosed information about GeneDx's business practices and financial health. As the lawsuit progresses, it is likely to uncover more details about the Company's alleged misconduct and the impact on its shareholders. Investors are advised to stay informed about the case's developments and consider their options for seeking compensation.

The genetic testing industry, in which GeneDx operates, is highly competitive and subject to intense regulatory scrutiny. The allegations against GeneDx highlight the importance of transparency and compliance with securities laws in this sector. Industry analysts are closely watching the outcome of this lawsuit, as it may set a precedent for future cases involving genetic testing companies.

As the class action lawsuit against GeneDx continues to unfold, investors will be keenly watching for updates on the Company's financial condition and business operations. The outcome of this case may have significant implications for GeneDx's future prospects and the broader genetic testing industry. Investors who have suffered losses due to GeneDx's alleged securities fraud may be able to recover damages by participating in the class action lawsuit.

In conclusion, the class action lawsuit against GeneDx Holdings Corp. is a significant development for investors who have been affected by the Company's alleged securities fraud. As the case progresses, it is essential for investors to remain informed and consider their options for seeking compensation. The Schall Law Firm is committed to protecting the rights of GeneDx investors and pursuing justice on their behalf.